534 Results

First Phase III trial of sulopenem + probenecid versus ciprofloxacin to treat women with UTI infections.- Iterum Therapeutics.

 Added 21 hours ago

Iterum Therapeutics plc , announced its initiation of the first of three Phase III clinical trials. In this trial, known...

Positive results from proof of concept trial of NuQ assay to diagnose prostrate cancer.- VolitionRx Ltd.

 Added 3 days ago

VolitionRx Limited has announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility...

FDA grants accelerated approval for Galafold treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.--Amicus Therapeutics.

 Added 5 days ago

Amicus Therapeutics has announced that the FDA has granted accelerated approval of Galafold (migalastat) 123 mg capsules. Galafold is an...

Hansa Medical initiates follow up study of patients treated with imlifidase (IdeS) prior to kidney transplantation.

 Added 10 days ago

Hansa Medical initiates follow up study of patients treated with lead candidate imlifidase (IdeS) prior to kidney transplantation. Hansa Medical...

Success for bardoxolone in patients with chronic kidney disease due to Alport syndrome shown in Phase II CARDINAL study and for polycystic kidney disease cohort of PHOENIX study.- Reata Pharma.

 Added 22 days ago

Reata Pharmaceuticals, Inc. announced results from two Phase II studies of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease...

FDA approves Xtandi for non-metastatic prostate cancer.- Astellas + Pfizer.

 Added 1 month ago

Astellas Pharma and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide), following FDA Priority...

CE Mark for the Sacral Neuromodulation External Trial System to treat urinary dysfunction.- Axonics Modulation Technologies, Inc.

 Added 1 month ago

Axonics Modulation Technologies, Inc., announced that it has received the CE mark for its Sacral Neuromodulation External Trial System to...

Study of Sonablate High Intensity Focused Ultrasound shows equivalence to surgery in prostate cancer.- SonaCare Medical.

 Added 1 month ago

SonaCare Medical reports 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate High Intensity Focused Ultrasound...

Results of Phase III PROSPER trial in Xtandi for prostate cancer published in New England Journal of medicine.- Astellas Pharma.

 Added 1 month ago

Astellas Pharma announced that results from the pivotal Phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy...

Phase III LEADERSHIP 301 trial of AQX 1125 fails to reach primary endpoint in interstitial cystitis/bladder pain syndrome.- Aquinox Pharma.

 Added 1 month ago

Aquinox Pharmaceuticals announced that the Phase III LEADERSHIP 301 clinical trial evaluating once-daily, oral AQX 1125 (rosiptor) for the treatment...

Load more